Log in
Enquire now
‌

AI Echocardiographic Screening of Cardiac Amyloidosis

OverviewStructured DataIssuesContributors

Contents

clinicaltrials.gov/study/NCT06664866
Is a
‌
Clinical study
0

Clinical Study attributes

NCT Number
NCT066648660
Health Conditions in Trial
‌
Cardiac amyloidosis
0
Trial Recruitment Size
5000
Trial Sponsor
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
0
Trial Collaborator
Northwestern Medicine
Northwestern Medicine
0
Clinical Trial Start Date
October 28, 2024
0
Primary Completion Date
November 1, 2025
0
Study Completion Date
November 1, 2026
0
Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Diagnostic0
Intervention Type
Diagnostic Test0
Interventional Trial Phase
Not Applicable0
Participating Facility
Northwestern Medicine
Northwestern Medicine
0
Official Name
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)0
Last Updated
October 31, 2024
0
Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0

Other attributes

Intervention Treatment
EchoNet-LVH Assessment0
Study summary

Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and accurately assess common measurements made in clinical practice. Echocardiography is the most common form of cardiac imaging and is routinely and frequently used for diagnosis. However, there is often subjectivity and heterogeneity in interpretation. Artificial intelligence (AI)'s ability for precision measurement and detection is important in both disease screening as well as diagnosis of cardiovascular disease. Cardiac amyloidosis (CA) is a rare, underdiagnosed disease with targeted therapies that reduce morbidity and increase life expectancy. However, CA is frequently overlooked and confused with heart failure with preserved ejection fraction. Some estimates suggest that CA can be as prevalence as 1% in a general population, with even higher prevalence in patients with left ventricular hypertrophy, heart failure, and other cardiac symptoms that might prompt echocardiography. AI guided disease screening workflows have been proposed for rare diseases such as cardiac amyloidosis and other diseases with relatively low prevalence but significant human impact with targeted therapies when detected early. This is an area particularly suitable for AI as there are multiple mimics where diseases like hypertrophic cardiomyopathy, cardiac amyloidosis, aortic stenosis, and other phenotypes might visually be similar but can be distinguished by AI algorithms. The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like AI Echocardiographic Screening of Cardiac Amyloidosis

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us